13-Fluorolysergol
Pharmaceutical compound
From Wikipedia, the free encyclopedia
13-Fluorolysergol, specifically as the (+)-enantiomer (+)-13-fluorolysergol, is a selective serotonin 5-HT2A receptor weak partial agonist or antagonist of the ergoline family.[1][2] It is highly selective for activation of the serotonin 5-HT2A receptor over the serotonin 5-HT2B and 5-HT2C receptors (EC50 = >10,000 nM).[1][2] (+)-13-Fluorolysergol has relatively weak maximal efficacy in activating the serotonin 5-HT2A receptor (Emax = 17%).[1][2] It is a derivative of lysergol.[1][2]
Other names(13-Fluoro-6-methyl-9,10-didehydroergolin-8β-yl)methanol
FormulaC16H17FN2O
| Clinical data | |
|---|---|
| Other names | (13-Fluoro-6-methyl-9,10-didehydroergolin-8β-yl)methanol |
| Drug class | Selective serotonin 5-HT2A receptor weak partial agonist or antagonist |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C16H17FN2O |
| Molar mass | 272.323 g·molâ1 |
| 3D model (JSmol) | |
| |
| |